Nuformix plc (LON:NFX – Get Free Report) shares dropped 10% during mid-day trading on Tuesday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 417,744 shares traded hands during trading, a decline of 96% from the average daily volume of 10,412,084 shares. The stock had previously closed at GBX 0.05 ($0.00).
Nuformix Stock Up 10.0 %
The company has a market capitalization of £450,620.50, a price-to-earnings ratio of -1.63 and a beta of 1.22. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The business’s 50 day moving average is GBX 0.05 and its 200 day moving average is GBX 0.11.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Stories
- Five stocks we like better than Nuformix
- What Do S&P 500 Stocks Tell Investors About the Market?
- Disney: Forging a 3-Headed Sports Streaming Giant With Fubo Deal
- High Dividend REITs: Are They an Ideal Way to Diversify?
- How Buffett’s Best and Worst Stock Bets Have Fared 5 Years Later
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bill Ackman’s Bold Case for Fannie Mae and Freddie Mac
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
